Validity of an automated telephonic system to assess COPD exacerbation rates

被引:15
作者
Bischoff, Erik W. M. A. [1 ]
Boer, Lonneke M. [2 ,3 ]
Molema, Johan [2 ]
Akkermans, Reinier [1 ]
van Weel, Chris [1 ]
Vercoulen, Jan H. [2 ,3 ]
Schermer, Tjard R. J. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Pulm Dis, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Med Psychol, NL-6500 HB Nijmegen, Netherlands
关键词
Chronic obstructive pulmonary disease; exacerbations; sensitivity; specificity; OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; FLUTICASONE PROPIONATE; ACTION PLAN; TRIALS; IMPACT; TIOTROPIUM; RECOVERY; THERAPY;
D O I
10.1183/09031936.00057811
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Current tools for recording chronic obstructive pulmonary disease (COPD) exacerbations are limited and often lack validity testing. We assessed the validity of an automated telephonic exacerbation assessment system (TEXAS) and compared its outcomes with existing tools. Over 12 months, 86 COPD patients (22.1% females; mean age 66.5 yrs; mean post-bronchodilator forced expiratory volume in 1 s 53.4% predicted) were called once every 2 weeks by TEXAS to record changes in respiratory symptoms, unscheduled healthcare utilisation and use of respiratory medication. The responses to TEXAS were validated against exacerbation-related information collected by observations made by trained research assistants during home visits. No care assistance was provided in any way. Diagnostic test characteristics were estimated using commonly used definitions of exacerbation. Detection rates, compliance and patient preference were assessed, and compared with paper diary cards and medical record review. A total of 1,824 successful calls were recorded, of which 292 were verified by home visits (median four calls per patient, interquartile range three to five calls per patient). Independent of the exacerbation definition used, validity was high, with sensitivities and specificities between 66% and 98%. Detection rates and compliance differed extensively between the different tools, but were highest with TEXAS. Patient preference did not differ. TEXAS is a valid tool to assess COPD exacerbation rates in prospective clinical studies. Using different tools to record exacerbations strongly affects exacerbation occurrence rates.
引用
收藏
页码:1090 / 1096
页数:7
相关论文
共 31 条
[1]   Counting, analysing and reporting exacerbations of COPD in randomised controlled trials [J].
Aaron, S. D. ;
Fergusson, D. ;
Marks, G. B. ;
Suissa, S. ;
Vandemheen, K. L. ;
Doucette, S. ;
Maltais, F. ;
Bourbeau, J. F. ;
Goldstein, R. S. ;
Balter, M. ;
O'Donnell, D. ;
FitzGerald, M. .
THORAX, 2008, 63 (02) :122-128
[2]  
[Anonymous], 2016, Fact Sheet
[3]  
[Anonymous], COCHRANE DATABASE SY
[4]   ANTIBIOTIC-THERAPY IN EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
ANTHONISEN, NR ;
MANFREDA, J ;
WARREN, CPW ;
HERSHFIELD, ES ;
HARDING, GKM ;
NELSON, NA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (02) :196-204
[5]   Effects of written action plan adherence on COPD exacerbation recovery [J].
Bischoff, Erik W. M. A. ;
Hamd, Dina H. ;
Sedeno, Maria ;
Benedetti, Andrea ;
Schermer, Tjard R. J. ;
Bernard, Sarah ;
Maltais, Francois ;
Bourbeau, Jean .
THORAX, 2011, 66 (01) :26-31
[6]   Sick leave in patients with obstructive lung disease is related to psychosocial and work variables rather than to FEV1 [J].
Boot, CRL ;
Vercoulen, JHMM ;
van der Gulden, JWJ ;
Orbon, KH ;
van den Hoogen, H ;
Folgering, HTM .
RESPIRATORY MEDICINE, 2005, 99 (08) :1022-1031
[7]   Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[8]  
BURGE S, 2003, EUR RESPIR J, V41, P46, DOI DOI 10.1183/09031936.03.00078002
[9]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[10]   Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease [J].
Donaldson, GC ;
Seemungal, TAR ;
Bhowmik, A ;
Wedzicha, JA .
THORAX, 2002, 57 (10) :847-852